Weak bones in diabetes mellitus - an update on pharmaceutical treatment options (Q47855337)

6 February 2018

http://europepmc.org/abstract/MED/28872686

title

Weak bones in diabetes mellitus - an update on pharmaceutical treatment options (English)

1 reference

6 February 2018

http://europepmc.org/abstract/MED/28872686

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28872686%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Daphne P L Lin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28872686%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

5 September 2017

1 reference

6 February 2018

http://europepmc.org/abstract/MED/28872686

published in

Journal of Pharmacy and Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28872686%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28872686%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28872686%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

1-17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28872686%20AND%20SRC:MED&resulttype=core&format=json

Diagnosis and classification of diabetes mellitus

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Pathophysiology of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Type 2 diabetes mellitus and fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

The pathophysiological role of PEDF in bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

21 January 2018

The amazing osteocyte

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Mechanisms of impaired bone strength in type 1 and 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Bone health in type 1 diabetes: focus on evaluation and treatment in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Understanding the pathology and mechanisms of type I diabetic bone loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Augmented LPS responsiveness in type 1 diabetes-derived osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Osteoclast receptors and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Vaspin attenuates RANKL-induced osteoclast formation in RAW264.7 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

The osteoblast: An insulin target cell controlling glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Osteoblast-Specific Loss of IGF1R Signaling Results in Impaired Endochondral Bone Formation During Fracture Healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

IGF-1 and IGF-binding proteins and bone mass, geometry, and strength: relation to metabolic control in adolescent girls with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Insulin-like growth factor-1 cytokines cross-talk in type 1 diabetes mellitus: relationship to microvascular complications and bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Effects of combined treatment of insulin and human parathyroid hormone(1-34) on cancellous bone mass and structure in streptozotocin-induced diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Safety of Anti-Diabetic Therapies on Bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Bone structure and turnover in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Determinants of bone strength and quality in diabetes mellitus in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

21 January 2018

Type 2 diabetes and bone

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Advanced Glycation End Products, Diabetes, and Bone Strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Diabetes and Its Effect on Bone and Fracture Healing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

A role for advanced glycation end products in diminished bone healing in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Thiazolidinediones and fracture risk in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Bone loss and fracture risk associated with thiazolidinedione therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Skeletal consequences of thiazolidinedione therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Bone is a target for the antidiabetic compound rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

The impact of diabetes and diabetes medications on bone health

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Sulfonylurea use and risk of hip fractures among elderly men and women with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Bone: incretin hormones perceiver or receiver?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes - A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Biology of stem cells: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Mesenchymal stem cells: cell biology and potential use in therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Mesenchymal stem cells (MSCs) as skeletal therapeutics - an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Alginate bead-encapsulated PEDF induces ectopic bone formation in vivo in the absence of co-administered mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Mesenchymal stem cells and bone regeneration: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Mesenchymal stem cells and bone regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Percutaneous injection of bone marrow mesenchymal stem cells for ankle non-unions decreases complications in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

The development of tissue-engineered bone of different origin through endochondral and intramembranous ossification following the implantation of mesenchymal stem cells and osteoblasts in a murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Bone morphogenetic protein-2 and bone therapy: successes and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

rhBMP-2 enhances the bone healing response in a diabetic rat segmental defect model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

The effect of locally delivered recombinant human bone morphogenetic protein-2 with hydroxyapatite/tri-calcium phosphate on the biomechanical properties of bone in diabetes-related osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Adverse events after recombinant human BMP2 in nonspinal orthopaedic procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label ph

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Teriparatide in patients with osteoporosis and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Successful treatment of nonunion with teriparatide after failed ankle arthrodesis for Charcot arthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Peroxisome proliferator-activated receptor gamma and metabolic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Bone defect regeneration and cortical bone parameters of type 2 diabetic rats are improved by insulin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Bone remodeling markers and bone metastases: From cancer research to clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Role of tartrate-resistant acid phosphatase (TRAP) in long bone development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12808

21 January 2018

Identifiers

DOI

10.1111/JPHP.12808

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28872686%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28872686%20AND%20SRC:MED&resulttype=core&format=json